University of Groningen Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction Posma,
暂无分享,去创建一个
M. Nijsten | D. J. Veldhuisen | P. Harst | D. Touw | K. Damman | E. Lipšic | I. Horst | C. P. Lexis | R. Posma
[1] P. McCullough,et al. Contrast-induced acute kidney injury. , 2018, Journal of the American College of Cardiology.
[2] Silvio E. Inzucchi,et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. , 2014, JAMA.
[3] R. McKelvie,et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. , 2014, Journal of the American College of Cardiology.
[4] G. Stone,et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. , 2014, European heart journal.
[5] J. Coresh,et al. GFR estimation: from physiology to public health. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] J. Kaski,et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. , 2014, The American journal of cardiology.
[7] B. Barrett,et al. Canadian Association of Radiologists Consensus Guidelines for the Prevention of Contrast-Induced Nephropathy: Update 2012 , 2014, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.
[8] Motohiro Kosugi,et al. Impact of contrast-induced acute kidney injury on outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. , 2013, Cardiovascular revascularization medicine : including molecular interventions.
[9] A. Hung,et al. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time‐dependent contribution of weight, blood pressure, and glycemic control , 2013, Pharmacoepidemiology and drug safety.
[10] Derek J Hausenloy,et al. Contrast‐induced acute kidney injury following PCI , 2013, European journal of clinical investigation.
[11] J. Bida,et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? , 2013, Radiology.
[12] D. Stakos,et al. Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention: a novel approach tailored to current practice. , 2013, International journal of cardiology.
[13] Wim Van Biesen,et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy† , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[15] R. D. de Boer,et al. Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial , 2012, Cardiovascular Drugs and Therapy.
[16] A. Hung,et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function , 2012, Kidney international.
[17] B. Pitt,et al. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study , 2012, Circulation.
[18] P. Aspelin,et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines , 2011, European Radiology.
[19] M. Caplan,et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. , 2011, American journal of physiology. Renal physiology.
[20] J. Wi,et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention , 2011, Heart.
[21] B. Zinman,et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[22] Y. Makino,et al. Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin , 2011, Diabetes.
[23] J. Spertus,et al. The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality. , 2010, American heart journal.
[24] X. Leverve,et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. , 2010, Kidney international.
[25] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[26] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[27] N. Kaplan. An updated meta-analysis with a few surprises. , 2005, Hypertension.
[28] G. Stone,et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. , 2004, Journal of the American College of Cardiology.
[29] D. Grobbee,et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.
[30] D. J. Veldhuisen,et al. Effect ofMetformin on Left Ventricular Function After AcuteMyocardial Infarction in PatientsWithout Diabetes The GIPS-III Randomized Clinical Trial , 2014 .
[31] J. Joles,et al. Cardiorenal syndrome—current understanding and future perspectives , 2014, Nature Reviews Nephrology.
[32] I. Malik,et al. Metformin: safety in cardiac patients. , 2010, Heart.